DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%

« Back to Dashboard

All Clinical Trials for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000468	Myocardial Infarction Triage and Intervention Project (MITI)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1988-04-01	To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00000468	Myocardial Infarction Triage and Intervention Project (MITI)	Completed	University of Washington	Phase 3	1988-04-01	To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00182143	PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)	Completed	Australian and New Zealand Intensive Care Society Clinical Trials Group	Phase 3	2006-05-01	The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143	PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)	Completed	Canadian Critical Care Trials Group	Phase 3	2006-05-01	The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143	PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)	Completed	Canadian Institutes of Health Research (CIHR)	Phase 3	2006-05-01	The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00182143	PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)	Completed	McMaster University	Phase 3	2006-05-01	The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
NCT00203580	Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)	Completed	Canadian Institutes of Health Research (CIHR)	Phase 4	1994-12-01	The purpose of this study is to assess the long-term treatment of patients with proximal venous thrombosis through the administration of subcutaneous low-molecular-weight heparin (tinzaparin sodium) versus the standard care use of intravenous heparin followed by oral warfarin sodium.

Clinical Trial Conditions for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%

Condition Name

Condition Name for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%
Intervention	Trials
Covid19	4
Myocardial Infarction	4
Thrombosis	4
Hemodialysis Catheter Infection	3

Condition MeSH

Condition MeSH for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%
Intervention	Trials
Thrombosis	10
Venous Thrombosis	7
Acute Kidney Injury	6
Thromboembolism	5

Clinical Trial Locations for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%

Trials by Country

Trials by Country for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%
Location	Trials
United States	41
Canada	14
Brazil	11
Germany	11
Italy	10

Trials by US State

Trials by US State for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%
Location	Trials
California	6
Texas	5
New York	5
Ohio	3
Massachusetts	2

Clinical Trial Progress for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%

Clinical Trial Phase

Clinical Trial Phase for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%
Clinical Trial Phase	Trials
Phase 4	26
Phase 3	12
Phase 2/Phase 3	4

Clinical Trial Status

Clinical Trial Status for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%
Clinical Trial Phase	Trials
Completed	32
Recruiting	14
Not yet recruiting	12

Clinical Trial Sponsors for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%

Sponsor Name

Sponsor Name for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%
Sponsor	Trials
Ain Shams University	5
Azidus Brasil	4
GlaxoSmithKline	4

Sponsor Type

Sponsor Type for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%
Sponsor	Trials
Other	108
Industry	29
NIH	5